FDA Moves Forward on Aducanumab
By
Phil Gutis
| August 7th, 2020
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
Alzheimer’s Drug Trials Have Had a 99% Failure Rate. The Good News: There Are Currently More Than 100 in the Pipeline
By
Phil Gutis
| July 30th, 2020
A survey of all drugs currently in clinical trials for Alzheimer’s disease found 121 unique therapies being tested in 136 Alzheimer’s drug trials. That…
Phil’s Journal: Being Part of Scientific History, or, a New Phase of the Biogen Trial
By
Phil Gutis
| July 16th, 2020
The latest news about Biogen’s controversial Alzheimer’s drug popped into my email at 8:26 a.m. last Wednesday. Coincidentally it arrived just as I was…
Phil’s Journal: Trials and Tribulations, or, My Latest Experience in Biogen Research
By
Phil Gutis
| June 9th, 2020
Well, I won’t try that again. Last week, I found myself bent over a table, resting my head on pillows as a doctor injected…
Phil’s Journal: Waiting While Approval for Biogen’s Alzheimer’s Drug is Delayed, Yet Again
By Phil Gutis | April 23rd, 2020
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…
Phil’s Journal: Pandemic Disrupts Alzheimer’s Clinical Trials. Including Mine
By Phil Gutis | March 25th, 2020
The response was disappointing but not particularly surprising. Earlier in the day, I had sent a quick email to check in with the staff…
Phil’s Journal: My Good Friend Is the First to Receive Biogen’s Alzheimer’s Drug in New Trial
By Phil Gutis | March 13th, 2020
Being Patient Senior Reporter Phil Gutis spent the day with our patient advisor, Jeff Borghoff, who was the first recipient in Biogen’s latest trial…
Follow us